4.5 Article

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer

Related references

Note: Only part of the references are listed.
Editorial Material Oncology

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Daniel B. Costa et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Medicine, General & Internal

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

Young Lim Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer

Eunice L. Kwak et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Oncology

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

Kengo Takeuchi et al.

CLINICAL CANCER RESEARCH (2008)

Article Oncology

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

Jussi P. Koivunen et al.

CLINICAL CANCER RESEARCH (2008)

Article Oncology

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

Kentaro Inamura et al.

JOURNAL OF THORACIC ONCOLOGY (2008)

Article Multidisciplinary Sciences

A mouse model for EML4-ALK-positive lung cancer

Manabu Soda et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)